Slide 1: FY24 AGM Presentation
FY24 AGM Presentation ASX: UCM • MedTech in active growth phase • Products and markets • Manufacturing and distribution partnerships • Rebound ready • Prepared for strategic restructure Prof. Rob Phillips Chairman and CEO, Uscom Limited Oct 25, 2024
Slide 2: Uscom Vision
Uscom Ltd I FY2024 Annual General Meeting I uscom.com.au Uscom Overview FY24 Results Uscom Markets Milestones FY25 Outlook Uscom Vision “A great company, with great vision, technology and culture, and a great global commercial opportunity” A Company for the Future Clinical Mission - To save lives ea
Slide 3: Uscom Medical Technology
Uscom Ltd I FY2024 Annual General Meeting I uscom.com.au Uscom Overview FY24 Results Uscom Markets Milestones FY25 Outlook Uscom Medical Technology Future growth from expanding products and global operations World leading medical technology (ASX:UCM) with global footprint – Sydney, Singapore, Beijin
Slide 4: Uscom - Revolutionising Hypertension
Uscom Ltd I FY2024 Annual General Meeting I uscom.com.au Uscom Overview FY24 Results Uscom Markets Milestones FY25 Outlook Uscom - Revolutionising Hypertension “Uscom – An innovator and leader in global MedTech” BP+ Non-invasive central BP monitoring Blue Prof Stephane Carlier, European Society of C
Slide 5: Uscom - Revolutionising Hypertension
Uscom Ltd I FY2024 Annual General Meeting I uscom.com.au Uscom Overview FY24 Results Uscom Markets Milestones FY25 Outlook Uscom - Revolutionising Hypertension “Uscom – An innovator and leader in global MedTech” Uscom * The Uscom BP+ is on the International Space Station for monitoring astronaut phy
Slide 6: Uscom - Revolutionising Preeclampsia
Uscom Ltd I FY2024 Annual General Meeting I uscom.com.au Uscom Overview FY24 Results Uscom Markets Milestones FY25 Outlook Uscom - Revolutionising Preeclampsia “Uscom – An innovator and leader in global MedTech” 17th October 2024 Prof Herbert Valensise New multi-centre randomised controlled trial de
Slide 7: Uscom - Revolutionising Asthma and COPD
FY21 Results Uscom Ltd I FY2024 Annual General Meeting I uscom.com.au Uscom Overview FY24 Results Uscom Markets Milestones FY25 Outlook Uscom - Revolutionising Asthma and COPD Next generation spirometry “Hospital in Home” – Asthma, COVID, COPD and Occupational Lung disease Applications - Research/CR
Slide 8: Uscom - Divisions and Diseases
FY21 Results Uscom Ltd I FY2024 Annual General Meeting I uscom.com.au Uscom Overview FY24 Results Uscom Markets Milestones FY25 Outlook Uscom - Divisions and Diseases Uscom specialised divisions Cardiac Vascular Uscom devices aid treatment of diseases responsible Pulmonary for >75% of all human mort
Slide 9: Publications - Clinical value
Uscom Ltd I FY2024 Annual General Meeting I uscom.com.au Uscom Overview FY24 Results Uscom Markets Milestones FY25 Outlook Publications - Clinical value Uscom - leader in world cardiovascular and pulmonary science >1,200 Peer reviewed publications 3 Global Guidelines Applications Emergency, Pediatri
Slide 10: Uscom Devices in World's Best Hospitals
Uscom Ltd I FY2024 Annual General Meeting I uscom.com.au Uscom Overview FY24 Results Uscom Markets Milestones FY25 Outlook Uscom Devices in World’s Best Hospitals Europe – Slovenjia – Lubiana Asia - China - Europe - Poland – Chongqing University Medical Center Lodz PERIN Chongqing Asia - China – Bei
Slide 11: FY24 Results
Uscom Ltd I FY2024 Annual General Meeting I uscom.com.au Uscom Overview FY24 Results Uscom Markets Milestones FY25 Outlook FY24 Results Returning to growth UCM Total Receipts Trend FY12 – FY25* $2.52 million $4.21 million 43% Cash on Hand Total Revenue Up sales of products Building the future Result
Slide 12: FY24 Results - by Region
Uscom Ltd I FY2024 Annual General Meeting I uscom.com.au Uscom Overview FY24 Results Uscom Markets Milestones FY25 Outlook FY24 Results - by Region A Year of Growth FY24 Regional Sales Growth Uscom Total Revenue by Region 70 66% 60 50 33% 35% Asia 45% 45% 43% Europe Europe 40 Asia US/Other US Austra
Slide 13: International Brands and eHealth
Uscom Ltd I FY2024 Annual General Meeting I uscom.com.au Uscom Overview FY24 Results Uscom Markets Milestones FY25 Outlook International Brands and eHealth Uscom Group International Brands International Brand Branding Sector 5 great International Brands across 3 product divisions Uscom is an emergin
Slide 14: Regulatory Approvals
Uscom Ltd I FY2024 Annual General Meeting I uscom.com.au Uscom Overview FY24 Results Uscom Markets Milestones FY25 Outlook Regulatory Approvals Global Progress ✓ Europe ✓ USCOM 1A: ✓ BP+: SpiroSonic: ✓ C h i n a , NMPA ✓ USCOM 1A: BP+: SpiroSonic: ✓ US ✓ USCOM 1A: ✓ ✓ BP+: SE Asia ✓ SpiroSonic: USCO
Slide 15: China Connection
Uscom Ltd I FY2024 Annual General Meeting I uscom.com.au Uscom Overview FY24 Results Uscom Markets Milestones FY25 Outlook China Connection China is growing with a mandated focus on advanced medical technology Manufacturing Partnership COVID Method Recommended method for COVID-19 treatment by Chines
Slide 16: Operational Milestones
Uscom Ltd I FY2024 Annual General Meeting I uscom.com.au Uscom Overview FY24 Results Uscom Markets Milestones FY25 Outlook Operational Milestones H.E. Mr. Graham Fletcher opening H.E. Mr. Graham Fletcher at Uscom’s Uscom’s manufacturing site in Beijing manufacturing site at Foxconn in Beijing Beijin
Slide 17: FY25 Drivers
Uscom Ltd I FY2024 Annual General Meeting I uscom.com.au Uscom Overview FY24 Results Uscom Markets Milestones FY25 Outlook FY25 Drivers “Uscom – A growing global MedTech” Growing a global MedTech platform New evidence – Sepsis, Hypertension, Preeclampsia New distribution – more management, more regi
Slide 18: Revenue Growth
Uscom Ltd I FY2024 Annual General Meeting I uscom.com.au Uscom Overview FY24 Results Uscom Markets Milestones FY25 Outlook Revenue Growth $21.6B USD $1.4B USD $1.3B USD 5yr CAGR 4.8% 8yr CAGR 11.2% 5yr CAGR 8.16% Cardiac BP and Vascular Pulmonary Products: USCOM 1A Products: BP+ & BP+ Reporter Produ
Slide 19: Looking forward
Uscom Ltd I FY2024 Annual General Meeting I uscom.com.au Uscom Overview FY24 Results Uscom Markets Milestones FY25 Outlook Looking forward “Vision, technology, culture, and a unique global opportunity” Rapidly growing clinical evidence supporting Uscom devices driving growth into an established and
Slide 20: Conclusion
Uscom Ltd I FY2024 Annual General Meeting I uscom.com.au Uscom Overview FY24 Results Uscom Markets Milestones FY25 Outlook Conclusion FY24 was a year of resumed growth for Uscom with a 43% rebound in total sales receipts following 10 consecutive years of >20% CAGR pre-COVID. Uscom has spent the COVI
Slide 21: Corporate Responsibility
Corporate Responsibility Australian Wildlife Conservancy (AWC) Australia is the extinction capital of the world In 15 years the list of threatened species has increased by 36% 87% of Australia’s mammals, 93% of our reptiles, 94% of our frogs, and 45% of our bird species are unique to Australia www.a
Slide 22: Questions and Comments
Questions and Comments ASX: UCM Prof. Rob Phillips Chairman and CEO, Uscom Limited Oct 25, 2024
Slide 23: Thank You
Thank You ASX: UCM Prof. Rob Phillips Chairman and CEO, Uscom Limited Oct 25, 2024